Tissue Engineering for Drug Development and Substance Testing
2019: Cell Sources and Stem Cell Generation for Drug Development
TEDD Annual Meeting brings together experts from diverse fields with a shared interest in advanced 3D models.
Primary and stem cells are becoming important sources for the generation of organotypic tissue models used in many biopharmaceutical applications, regenerative medicine, disease modelling and drug discovery. They promise to revolutionize the drug discovery process at all stages, from target identification through to toxicology studies.
While primary cells by nature represent the native tissue most accurately, they usually have limited capacity to divide and thus need to be freshly isolated for each assay limiting their application. In contrast the ability of stem cells to generate physiologically relevant cells in limitless supply makes them an attractive alternative to currently used recombinant cell lines or primary cells. Emerging technologies involve the production of organoids from human pluripotent stem cells (hPSCs) and the use of organ-on-a-chip devices. These approaches are showing great promise for developing a more reliable, rapid and cost-effective process when compared with the current use of animal models.
The current challenges include routinely directing stem cell differentiation to reproducibly and cost-effectively generate pure specific lineages.
During TEDD Annual Meeting, we have discussed how stem cells have already been used in the drug discovery process and how novel technologies can be applied to attain widespread adoption of stem cell technology by the pharmaceutical and biotech industry.
24th October 2019
Zurich University of Applied Science (ZHAW), Campus Grüental 8820 Wädenswil (Switzerland)
Access only for TEDD members: contact email@example.com for password.
2018: Advanced in vitro models analysis
During the past two decades, we have witnessed significant scientificand technical advances in the fields of drug discovery and translational medicine along with advances in predictive in vitro model systems. As of now, microfabrication techniques and tissue engineering have enabled the development of a wide range of 3D cell culture technologies, including multicellular spheroids, organoids, scaffolds, hydrogels, organson-chips, and 3D bioprinting, each with its own advantages and disadvantages. 3D culture models have been penetrating into the early drug discovery process, starting from disease modeling to target identification and validation, screening, lead selection, efficacy, and safety assessment. However, challenges remain in standardization with respect to culture and assay protocols, phenotypes, and gathering output data for analysis. Assays using 3D cell models are far more complex and less developed with respect to imaging, analysis, quantification, and automation compared with established 2D methods. Improvements in imaging modality, data acquisition throughput, and analysis tools are necessary for the wide adoption of 3D cell cultures for screening. Regulatory authorities have yet to accept data obtained from 3D cell models, such as organoids or organs on-chips, as a surrogate for preclinical animal testing. This year’s TEDD Annual Meeting brings together experts from diverse fields with a shared interest in advanced 3D models. The idea is to help to foster collaborations between 3D cell culture developers, and experts in advanced analysis methods: microscopy, sensors, data modelling and high-throughput screening. Several companies will exhibit during our famously long lunch break at the Greenhouse, where we have the opportunity to interact. Join us for this meeting to celebrate another fruitful collaboration year with the new perspectives ahead.
The KVET association accreditated TEDD AM 2018 as worth 0.5-day continuing education. Participants interested in receiving the certificate should contact Dr Kasia Kopanska at firstname.lastname@example.org.
Date and location
- 21 October 2018
- ZHAW, Campus Grüental, Wädenswil
2017: Bioprinting-where to go?
This year the TEDD Annual Meeting is dedicated to the field of bioprinting. The technology is expected to change the way we engineer tissues and bring it to a new level of physiological relevance. This will have an impact on drug development and substance testing, as well as clinical research and personalized medicine. We will hear about the latest developments of bioprinting in basic and applied research, as well as industrial applications. What are the benefits of bioprinting compared to standard tissue engineering approaches and where do we see a real added value?
As usual there will be an exhibition over lunch time, where industrial partners will present their latest technologies and ideas. This platform will enable discussions, collaborations and the generation of new network projects.
For the first time a workshop on bioprinting is preceding the TEDD AM where the two companies regenHU Ltd. and CellINK demonstrate their applications and collaborations.
Date and location:
- Workshop: 8 November 2017 (13.00 - 16.30), Campus Reidbach, RT 505
- Symposium: 9 November 2017 (full day), Campus Grüental, GA 203
2016: 50 shades of 3D: from ultraflat 3D to recellularised organs. Harnessing the constructional and metabolic potential of human cells in vitro
- Metabolic Tissue Engineering: a tale of two fats, Dr. Michael Raghunath, Head of TEDD Competence Centre, Zurich University of Applied Sciences (ZHAW)
- Regulation of brown fat formation and function, Prof. Dr. Christian Wolfrum, ETH Zurich, Department of Health Sciences and Technology, Switzerland
- Complex vascularized tissue models and their application, Prof. Dr. Heike Walles, Department Tissue Engineering & Regenerative Medicine (TERM, University Hospital Würzburg), Translational Center Würzburg, Regenerative Therapies in Oncology and Musculoskeletal Disease Würzburg, branch of the Fraunhofer Institut Interfacial Engineering and Biotechnology (IGB), Germany
- Human 3D-cocultures for the study of liver fibrosis, Prof. Dr. Laura Suter-Dick, University of Applied Sciences and Arts Northwestern Switzerland
- Adding metabolic competence to 3D cell-based assays using a spheroid-based microphysiological system, Dr. Olivier Frey, InSphero AG, Switzerland
- Fabrication of functional human skeletal muscle tissue for drug testing using 3D bioprinting, Dr. Hansjoerg Keller, Novartis Institutes for BioMedical Research, Switzerland
- Engineering human hair follicles in vitro – opportunities in regenerative medicine and cosmetics testing, Dr. Uwe Marx, TissUse GmbH, Germany
- Evaluation by 3D imaging of the molecular activity in pre-clinical phases, Dr. Jean-Michel Lagarde, imactiv-3d, France
- SiMPLInext SA - Hi-Fi in vitro. Delivering on the promises of permeable supports for tissue engineering, Dr. Silvia Angeloni Suter, CSEM & SiMPLInext, Switzerland
- Application of human cell culture techniques to create cosmetic stories, Dr. Fred Zülli, Mibelle Group, Switzerland
- Final remarks and TEDD next steps, Dr. Michael Raghunath, Head of TEDD Competence Centre, Zurich University of Applied Sciences (ZHAW)
2015: Moving 3D cell cultures from bench to practice
- TEDD Report 2015, Prof. Dr. Ursula Graf-Hausner, ZHAW, Head of TEDD Competence Centre
- Increasing biological relevance in vitro: From single microtissues to micro-physiological systems, Dr. Jens Kelm, InSphero AG
- Cell-instructive Polymer Matrix Platforms, Prof. Dr. Carsten Werner, Leibniz-Institut für Polymerforschung Dresden e.V., Max Bergmann Center of Biomaterials and Technische Universität Dresden, Center for Regenerative Therapies Dresden, Germany
- Potential of Macroporous Hydrogels as Biomimetic 3D Bone Marrow Analogs, Dr. Cornelia Lee-Thedieck, Karlsruhe Institute of Technology (KIT), Institute of Functional Interfaces, Eggenstein-Leopoldshafen, Germany
- Predictive 3D Lung Models for Inhalation Toxicology, Barbara Rothen-Rutishauser, Adolphe Merkle Institute University of Fribourg
- New 3D Biomimetic Hydrogel to Deliver Factors Secreted by Human Mesenchymal Stem Cells in Spinal Cord Injury, Prof. Dr. Giuseppe Perale, University of Applied Sciences and Art of Southern Switzerland SUPSI, Manno
- Multi-scale Functional Imaging of Tendon: Bench and Bedside, Prof. Dr. Jess Snedeker, University and ETH Zurich
- Simple Assays for Complex Biology, Dr. Christian Parker, Novartis Institute for BioMedical Research
- Parallel Preparation of RAFT 3D Cell Cultures on the Freedom EVO, Dr. Isabel Patocchi, Tecan
- Hyaluronic Acid Scaffold for 3D Cell Culture, Dr. Elise Demange, Celenys, France
- A Claim Substantiation for Resveratrol as an Inhibitor of Skin Pigmentation using Reconstructed Human Pigmented Epidermis, Dr. Remo Campiche, DSM Nutritional Products, Kaiseraugst
- Revolutionizing Organ-on-a-chip Technology: Any Throughput, Any Complexity, Anywhere, Dr. Jos Joore, Mimetas, Leiden, Holland
- Final remarks and TEDD next steps, Prof. Dr. Ursula Graf-Hausner, ZHAW, Head of TEDD Competence Centre
2014: 3D-cell culture with perspectives for medicine and animal welfare
- TEDD and NFP information, Prof. Dr. Ursula Graf-Hausner, ZHAW
- Needs, dreams and reality about in vitro toxicology cellular assays for the pharmaceutical industry, Dr. Francois Pognan, Novartis Institute for BioMedical Research, Basel
- From basic research to clinically applicable skin grafts, Prof. Dr. Ernst Reichmann, Tissue Biology Research Unit, University Children’s Hospital Zurich
- Predicting therapy for the individual breast cancer patient using the tissue originated spheroid model, PD Dr. Barbara Mayer, SpheroTec GmbH
- 55 years of 3Rs: Where do we stand, where are we going?, Dr. Stefanie Schindler, Animalfree Research, Bern
- TEDD next steps, Prof. Dr. Ursula Graf-Hausner, ZHAW
2013: 3D cell cultures - a promising key technology for drug testing
2012: Pioneering research using human tissue models in drug development
- Competence Centre TEDD, Prof. Dr. Ursula Graf-Hausner, ZHAW
- Science and Industry: Realizing visions together, Dr. Oliver Peter, Acetelion
- The future of 3D cell culture in drug development, Dr. David W. Grainger, University of Uta